|Previous Section||Index||Home Page|
(90) Provisional data
Yvette Cooper [holding answer 7 February 2002]: Measles vaccine was replaced with MMR from October 1988. Since then each of the manufacturers have advised the Department that they no longer intended to supply single measles vaccine to the United Kingdom.
Tim Loughton: To ask the Secretary of State for Health what figures he has collected for MMR vaccination rates in the October to December 2001 quarter in the UK, broken down by health authority area. 
When published the information about coverage rates by region for children who have received a primary MMR vaccination by their second birthday and a booster vaccination by age five is contained in the Statistical Bulletin "NHS Immunisation Statistics,
25 Feb 2002 : Column 950W
England: 2000/01". A copy of the bulletin will be placed in the Library and can also be found on the Department of Health website www.doh.gov.uk/public/sb0121.htm.
Yvette Cooper: We do not keep a database of single component MMR vaccines licensed in European Union member states. However, all EU member states recommend a two dose vaccination schedule with MMR vaccine. None routinely recommend single vaccines instead of MMR.
There is no comprehensive list available of measles, mumps and rubella combination vaccines, two-component vaccines or single component vaccines that are currently licensed in Europe . The Medicines Control Agency has obtained the following information from "The European Drug Index" (1997 edition), from national compendia of licensed medicinal products in France, Germany, Switzerland and Sweden (1998 to 2000 editions), and from two companies. While these references indicate that such products are currently licensed as listed in the named countries, it is not known whether or not they are on the market at the present time.
Measles plus rubella vaccines are licensed in at least Italy, Switzerland and the UK.
Measles plus mumps vaccines are licensed in at least Germany, Portugal and Switzerland.
At least one measles single component vaccine is licensed in Italy, Belgium, France, Germany, Austria, Netherlands, Switzerland, Portugal, Spain, Greece and the UK.
At least one single component mumps vaccine is licensed in Italy, Belgium, Germany, Austria, Netherlands, Switzerland, Portugal and the UK.
There are numerous single component rubella vaccines licensed across the EU, including the UK.
Mr. Burstow: To ask the Secretary of State for Health what statistics his Department collects concerning (a) (i) primary and (ii) contributory diagnosis relating to malnutrition and (b) the weight of patients on (1) admission and (2) discharge from hospital by age. 
Yvette Cooper [holding answer 4 February 2002]: The Department collects information on in-patients as part of the hospital episodes statistics (HES) system, which contains details of patients admitted to and treated in
25 Feb 2002 : Column 951W
National Health Service hospitals in England. HES records contain up to seven diagnoses (coded to ICD10 where malnutrition is E40 to E46). The first of these is the main reason that the patient was in hospital; any
25 Feb 2002 : Column 952W
subsidiary or secondary diagnoses are recorded in the last six fields. Admissions to hospital with a main diagnosis of malnutrition, by age, are given in the table.
|85 and over||35||27||31||22||24||27|
Admissions are defined as the first period of patient care under one consultant within one healthcare provider. Please note that admissions do not represent the number of patients, as a person may have more than one admission within the year. Figures have not yet been adjusted for shortfalls in data (i.e. the data is ungrossed).
Hospital Episode Statistics (HES), Department of Health.
Mr. Hutton: National Health Service Estates, an executive agency of the Department of Health, provides advice and guidance to the NHS, principally through a series of documents. These represent best practice guidance, and through their adoption, NHS trusts and health authorities should comply with current legislation affecting disabled people.
NHS Estates guidance document "Car Parking" (1996Health Facilities Note 21) suggests overall proportion of car park spaces for disabled people for healthcare premises, whilst accepting that the number and different types of car park spaces would be dependent on the range of healthcare services and facilities provided.
The Department also issued "Doubly DisabledEquality for Disabled People in the new NHSAccess to Services" (1999). This guidance gives advice on accessibility for disabled people including 'Transport, cars and parking'. To help underpin this process, an access audit tool was developed and made available to all NHS bodies in 1999.
Mr. Hutton: [holding answer 4 February 2002]: Data are not collected on the number of patients waiting for angiograms. On the 21 November 2001, we announced details of the first wave of £65 million of New Opportunities Fund money which will provide new angiography equipment at 37 hospitals. This was matched by £15 million from the Treasury Capital Modernisation Fund to be used on building laboratory facilities for angiography at 22 hospitals. Further Treasury Capital Modernisation Fund money for buildings will follow to match second and third wave New Opportunities Fund funding. This first wave of funding will enable the National Health Service to carry out an extra 14,000 angiograms each year, and so reduce waiting times.
Yvette Cooper: [holding answer 5 February 2002]: A Commission for Health Improvement team revisited University Hospitals Coventry and Warwickshire NHS Trust, which includes Walsgrave General Hospital, to assess progress in implementing the trust's action plan, following a clinical governance review last year. The visit took place on 2223 January 2002, and a report is due to be published in March 2002.
|Next Section||Index||Home Page|